QPharma has introduced a new digital sampling platform designed to improve healthcare provider (HCP) engagement at medical congresses. The launch highlights how compliant technology and in-person representative support can work together to modernize pharmaceutical sampling.
At a recent national medical congress, QPharma demonstrated its digital sampling platform under the theme “Engage & Access.” The initiative showcased a compliant, conference-based solution that blends intuitive digital tools with personal engagement from pharmaceutical representatives. As a result, HCPs can request samples more efficiently while remaining within strict regulatory guidelines.
Addressing the Gap in Congress-Based Sampling
Medical congresses create valuable opportunities for scientific exchange. However, traditional post-event sample follow-ups often delay action. For example, Direct-to-Practitioner (DTP) requests submitted after conferences may lose momentum once physicians return to daily practice.
Therefore, QPharma’s digital sampling platform focuses on enabling real-time engagement. By meeting HCPs in the moment, the solution helps convert interest into action while maintaining compliance at every step.
How the Digital Sampling Platform Works
To solve this challenge, QPharma collaborated with pharmaceutical partners to build a dual-platform system tailored for live events.
The initiative includes:
-
On-site kiosk interface: A touchscreen system that allows quick and guided sample requests. Importantly, every transaction requires the presence of a pharmaceutical representative. This ensures product detailing, fair-balance communication, and PDMA-compliant documentation.
-
On-site “Briefcase” microsite: A secure digital hub where HCPs can review efficacy and safety data, connect with representatives, access formulary information, and request samples in a streamlined manner.
Together, these tools create a structured yet flexible digital sampling platform that supports both engagement and accountability.
Compliance and Regulatory Oversight
Innovation in pharmaceutical sampling must align with regulatory standards. Accordingly, QPharma ensured that the program met all PDMA requirements, as well as 21 CFR Part 203 and Part 11 guidelines. In addition, the initiative passed Legal, Medical, and Regulatory (LMR) review.
All compliance elements, including data privacy controls, representative interactions, and fulfillment logistics, were documented through Titanium’s audit-trail capabilities. Notably, no samples were dispensed on-site. Instead, shipments were sent directly to verified practitioner addresses.
Jitesh Rohatgi, Chief Technology Officer at QPharma, emphasized that the approval process demonstrated that digital innovation and regulatory discipline can move forward together. By building solutions within established boundaries, the company aims to set a new benchmark for compliant HCP engagement at industry events.
Overall, QPharma’s digital sampling platform positions the company at the forefront of technology-enabled, regulation-ready healthcare engagement.
Read Also: Best Travel Insurance for Pre-Existing Conditions 2026: Generali Global Assistance Recognized
